scholarly journals Meta-Analysis: The Clinical Application of Autologous Adult Stem Cells in the Treatment of Stroke

2021 ◽  
Vol Volume 14 ◽  
pp. 81-91
Author(s):  
Noora Hassani ◽  
Sebastien Taurin ◽  
Sfoug Alshammary
2013 ◽  
Vol 31 (6) ◽  
pp. 323-334 ◽  
Author(s):  
Ali Ghodsizad ◽  
Arjang Ruhparwar ◽  
Viktor Bordel ◽  
Ebrahim Mirsaidighazi ◽  
Hans Michael Klein ◽  
...  

2019 ◽  
Vol 55 (1) ◽  
pp. 1-12 ◽  
Author(s):  
Solen Novello ◽  
Alexandre Debouche ◽  
Marie Philippe ◽  
Florian Naudet ◽  
Sylvie Jeanne

2019 ◽  
Vol 47 (7) ◽  
pp. 1722-1733 ◽  
Author(s):  
Wenyan Zhou ◽  
Junxin Lin ◽  
Kun Zhao ◽  
Kaixiu Jin ◽  
Qiulin He ◽  
...  

Background: Mesenchymal stem cells (MSCs) can be isolated from various tissues and can present themselves as a promising cell source for cell-based therapies. Although adipose- and bone marrow–derived mesenchymal stem cells have already been used in a considerable number of clinical trials for osteoarthritis treatment, systematic analyses from single- to bulk-cell resolution as well as clinical outcomes of these 2 MSCs are still insufficient. Purpose: To explore the characteristics and differences of adipose-derived stem cells (ADSCs) and bone marrow MSCs (BMSCs) at single- and bulk-cell levels, to study the clinical outcomes of these 2 cells on the treatment of osteoarthritis, and to provide potential guidance on the more precise clinical application of these MSCs. Study Design: Controlled laboratory study and meta-analysis. Methods: Same donor–derived ADSCs and BMSCs were isolated and cultured. Single- and bulk-cell assays were used to identify the characteristics of these 2 cells. Meta-analysis of clinical trials was done to compare the clinical therapeutic effects in osteoarthritis treatment with ADSCs and BMSCs. Results: Single-cell RNA sequencing analysis showed that the population of ADSCs showed lower transcriptomic heterogeneity when compared with BMSCs. Additionally, as compared with BMSCs, ADSCs were less dependent on mitochondrial respiration for energy production. Furthermore, ADSCs had a lower expression level of human leukocyte antigen class I antigen and higher immunosuppression capacity when compared with the BMSC population. Meta-analysis of current clinical trials of osteoarthritis treatment with MSCs consistently showed that ADSCs are more stable than BMSCs in their therapeutic effect. Conclusion: These results provide basic biological insights into human ADSCs and BMSCs at the single-cell resolution. Findings indicated that ADSCs may be a more controllable stem cell source, may be more adaptable to surviving in the hypoxic articular cavity niche, and may exhibit superiority in regulating inflammation. Based on the meta-analysis results of the different characteristics of ADSCs and BMSCs, ADSCs were implicated as being a better cell source for osteoarthritis treatment. Clinical Relevance: These results guide a more precise clinical application of adipose and bone marrow mesenchymal stem cells.


2005 ◽  
Vol 53 (S 3) ◽  
Author(s):  
W Röll ◽  
T Hashemi ◽  
M Breitbach ◽  
O Dewald ◽  
A Welz ◽  
...  

2013 ◽  
Vol 20 (28) ◽  
pp. 3429-3447 ◽  
Author(s):  
Stefania Pagliari ◽  
Sara Romanazzo ◽  
Diogo Mosqueira ◽  
Perpetua Pinto-do-O ◽  
Takao Aoyagi ◽  
...  

Author(s):  
Mohammad Saeedi ◽  
Muhammad Sadeqi Nezhad ◽  
Fatemeh Mehranfar ◽  
Mahdieh Golpour ◽  
Mohammad Ali Esakandari ◽  
...  

: Mesenchymal stem cells (MSCs), a form of adult stem cells, are known to have a self-renewing property and the potential to specialize into a multitude of cells and tissues such as adipocytes, cartilage cells, and fibroblasts. MSCs can migrate and home to the desired target zone where inflammation is present. The unique characteristics of MSCs in repairing, differentiation, regeneration, and its high capacity of immune modulation has attracted tremendous attention for exerting them in clinical purposes, as they contribute to tissue regeneration process and anti-tumor activity. The MSCs-based treatment has demonstrated remarkable applicability towards various diseases such as heart and bone malignancies, and cancer cells. Importantly, genetically engineered MSCs, as a state-of-the-art therapeutic approach, could address some clinical hurdles by systemic secretion of cytokines and other agents with a short half-life and high toxicity. Therefore, understanding the biological aspects and the characteristics of MSCs is an imperative issue of concern. Herein, we provide an overview of the therapeutic application and the biological features of MSCs against different inflammatory diseases and cancer cells. We further shed light on MSCs physiological interaction, such as migration, homing, and tissue repairing mechanisms with different healthy and inflamed tissues.


Sign in / Sign up

Export Citation Format

Share Document